Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

MOTS-c vs SS-31 (elamipretide)

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: favors SS-31 (elamipretide)

SS-31 (elamipretide) has the stronger evidence and regulatory standing: it has been tested in randomized human trials and received FDA accelerated approval as Forzinity for Barth syndrome in September 2025. MOTS-c has only mouse treatment data and human blood level associations. The caveat is that SS-31's trials were mixed, including a 218 patient mitochondrial myopathy trial that missed its primary endpoint, so neither peptide is proven for general mitochondrial health, energy, or aging.

Verified: Verified Oct 28, 2026
MOTS-cSponsoredFrom Bodybuilding Peptides

Which is better, MOTS-c or SS-31 (elamipretide)?

SS-31 wins on evidence grade (human RCT versus animal only) and regulatory status (an FDA approved drug versus a substance that is not on the 503A bulks list and is covered only by HHS's October 28, 2026 draft enforcement discretion policy, which is not an approval). Its approval is narrow, limited to Barth syndrome and based on a small crossover trial that missed its primary endpoints plus a 168 week open label extension, and MMPOWER-3 found no benefit over placebo in primary mitochondrial myopathy. MOTS-c has no human treatment trial at all. [1] [5] [6] [7] [8] [10] [13]

How do MOTS-c and SS-31 (elamipretide) compare?

MOTS-c and SS-31 (elamipretide) compared by dimension
DimensionMOTS-cSS-31 (elamipretide)Favored
Evidence grade [1] [2] [3] [5] [6]Animal only. Mouse metabolic and exercise studies; human data are exercise induced blood levels and a genetic association with type 2 diabetes.Human RCT. TAZPOWER (12 patients with Barth syndrome) and MMPOWER-3 (218 adults with primary mitochondrial myopathy), plus earlier phase 2 trials.
Mechanism [1] [4]A 16 amino acid peptide encoded by mitochondrial DNA that signals outward: it activates AMPK via the folate cycle and AICAR, raising muscle glucose uptake and fat oxidation.A synthetic tetrapeptide that works inside mitochondria: it binds cardiolipin on the inner membrane, stabilizing cristae and respiratory chain supercomplexes and improving ATP production.
Key trial results [1] [2] [5] [6] [7]No human treatment trial. In mice, prevented diet induced obesity and insulin resistance and improved running capacity at all ages.TAZPOWER missed its 12 week crossover endpoints but the open label extension showed sustained gains in 6 minute walk distance and strength at 168 weeks; MMPOWER-3 showed no significant difference from placebo at 24 weeks.
Human safety data [1] [6] [7]None published. Theoretical added glucose lowering with diabetes drugs based on mouse data.Generally well tolerated in trials; injection site reactions were the most common adverse event, with headache, dizziness, and eosinophilia in some participants.
FDA and compounding status [8] [9] [10] [13] [14]Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection only) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B).FDA approved (accelerated approval, Forzinity, September 2025) for Barth syndrome. Because an approved product exists, it is not eligible for routine 503A compounding.
WADA status [11]Prohibited at all times under S4.4 (metabolic modulators), where it is named as an activator of AMP-activated protein kinase.Not prohibited.
Note: Because elamipretide is now an approved drug, it no longer falls under S0.
Human dosing reference [1] [2] [6] [8]Not established. Mice received 0.5 mg/kg daily (metabolic studies) up to 15 mg/kg (exercise studies).Trials used 40 mg subcutaneously once daily; the Forzinity label gives weight based dosing for Barth syndrome.
Access path [8] [10] [13]Only as a single-ingredient compounded product on a patient-specific prescription under HHS's October 28, 2026 draft enforcement discretion policy, if its conditions are met; it is not on the 503A bulks list.Specialist prescription for Barth syndrome through specialty pharmacy; other uses only in clinical trials. Research listings labeled SS-31 are not the approved drug.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

MOTS-c and SS-31 (elamipretide): grade, status, and cost
AttributeMOTS-cSS-31 (elamipretide)
ClassMitochondrial derived peptide (16 amino acids) encoded in the 12S rRNA region of mitochondrial DNASynthetic mitochondria targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that binds cardiolipin on the inner mitochondrial membrane
What it isA 16 amino acid peptide coded by mitochondrial DNA that improves metabolism and exercise capacity in mice; human data limited to blood levels and genetics.Mitochondria targeted peptide FDA approved in 2025 as Forzinity for rare Barth syndrome, after a large mitochondrial muscle disease RCT missed its main goal.
EvidenceEvidence: Animal-only evidenceEvidence: Human RCT evidence
FDA statusRegulatory: HHS interim policy (draft)Regulatory: FDA approved
CompoundingMOTS-c is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds MOTS-c when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add MOTS-c to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.FDA granted accelerated approval to elamipretide (Forzinity) in September 2025 for Barth syndrome, making it the first approved treatment for that disease. Because an FDA approved product exists, elamipretide is not eligible for routine 503A compounding, and it has not been listed on the 503A bulks list. Material sold online as SS-31 for research use is not the approved drug; sold for human use, it is an unapproved drug.
WADAWADA: WADA prohibitedWADA: Not WADA prohibited
RoutesSubcutaneous injection (as sold), Intraperitoneal injection (animal studies)Subcutaneous injection once daily (Forzinity label and trials), Intravenous infusion (earlier cardiac and kidney trials)
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient MOTS-c on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.Forzinity pricing for Barth syndrome is set for a rare disease and is largely covered through specialty pharmacy and manufacturer patient programs; a cash price is not publicly listed. Research chemical listings for SS-31 exist, but those products are unapproved drugs when sold for human use.
Last verified

Has MOTS-c been tested directly against SS-31 (elamipretide)?

No published trial has compared MOTS-c and SS-31 (elamipretide) directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do MOTS-c and SS-31 (elamipretide) cost?

Typical cost of MOTS-c and SS-31 (elamipretide)
DimensionMOTS-cSS-31 (elamipretide)
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient MOTS-c on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.$66,000 per month
Price detailMOTS-c price by channelForzinity (SS-31) cost

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the MOTS-c page.

Frequently asked questions

Which is better for mitochondrial health or energy?

Neither has been shown to improve energy or mitochondrial health in healthy people. SS-31 is approved only for Barth syndrome and did not beat placebo in adults with primary mitochondrial myopathy in MMPOWER-3. MOTS-c has only mouse data. [2] [6] [8]

Is SS-31 FDA approved?

Yes. Elamipretide received accelerated approval as Forzinity in September 2025 for Barth syndrome, supported by the TAZPOWER trial and its 168 week open label extension. Products sold online as SS-31 for research are not the approved drug; sold for human use, they are unapproved drugs. [5] [7] [8] [12]

Can I get MOTS-c from a compounding pharmacy?

Possibly, under conditions. MOTS-c is not FDA approved or on the 503A bulks list, but it is covered by HHS's October 28, 2026 draft enforcement discretion policy, which says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection only) on a patient-specific prescription, when sourcing, testing, and adverse event reporting conditions are met. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. Research-use-only products sold for human use are still unlawful, and state law still applies. [9] [10] [13] [14]

Do they work the same way?

No. SS-31 acts inside the mitochondrion by binding cardiolipin and stabilizing the respiratory chain. MOTS-c is a signaling peptide made from mitochondrial DNA that acts on the cell's metabolism through AMPK. [1] [4]

Are they allowed for tested athletes?

MOTS-c is prohibited at all times under WADA section S4.4 (metabolic modulators). SS-31 is not prohibited now that it is an approved drug, though athletes should confirm against the current list. [11]

Conditions studied

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015PubMed 25738459, 2015
  2. [2]Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021PubMed 33473109, 2021
  3. [3]Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY) 2021PubMed 33468709, 2021
  4. [4]Birk AV et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 2013PubMed 23813215, 2013
  5. [5]Reid Thompson W et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med 2021 (TAZPOWER)PubMed 33077895, 2021
  6. [6]Karaa A et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology 2023PubMed 37268435, 2023
  7. [7]Thompson WR et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med 2024PubMed 38602181, 2024
  8. [8]FDA prescribing information for Forzinity (elamipretide) injection, via DailyMedFDA
  9. [9]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
  10. [10]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). MOTS-c vs SS-31 (elamipretide): evidence, cost, and legality. https://peptideagent.ai/compare/mots-c-vs-ss-31
HTML link
<a href="https://peptideagent.ai/compare/mots-c-vs-ss-31">MOTS-c vs SS-31 (elamipretide): evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.